



FINAL ORAL & POSTER PROGRAMS

The 14th International Conference on

Human Antibodies & Hybridomas

12-14 November 2008, New York University, New York, USA

Sponsored by the International Journal Human Antibodies

In association with the Integrative Medical Sciences Association

Program Chairman: *Professor Mark Glassy (IMSA, San Diego, USA)*

Scientific Advisory Committee

*Local Organiser: Mirek Gorny (New York University School of Medicine, New York, USA)
Zdenka L. Jonak (GlaxoSmithKline, USA) · Peter Vollmers (University of Würzburg, Germany)
J. Donald Capra (OHRF, USA) · Roberto Burioni (Universita Vita-Salute San Raffaele, Milan, Italy)
Dee Athwal (Moksha 8, UK) · Yan Wu (ImClone Systems Inc., New York, USA)
Kathy Potter (Southampton University, UK) · Jim Larrick (Panorama Research Inc., USA)
Alois Lang (GeNeuro SA, Geneva, Switzerland) · David P. Humphreys (UCB-Celltech, Slough, UK)
Matthew Downham (MorphoSys AG, Martinsried, Germany) · Eszter Nagy (InterCell AG, Vienna, Austria)
Henry Lowman (Genentech Inc., USA) · Sachdev Sidhu (University of Toronto, Canada)*

HUMAN ANTIBODIES & HYBRIDOMAS 2008
 THE 14TH INTERNATIONAL CONFERENCE



Conference Program – Wednesday 12th November 2008

08.00am Onwards

Registration

SESSION 1:

OPENING PLENARY SESSION

Moderator: Professor Mark Glassy
(HAH 2008 Conference Chairman)

09.30-10.30

Opening Plenary Lecture:

'B cells purloin repair to generate antibody diversity'
Matthew Scharff (AECOM, New York, USA)

10.30-11.00

Coffee Break Et Poster Set-Up

SESSION 2:

CANCER I

Moderator: Mark Glassy (HAH 2008 Conference Chairman)

11.00-11.30

'Natural immunity, the one and only source for cancer-specific therapeutics?'

H. Peter Vollmers (University of Wurzburg, Germany)

11.30-11.50

'Targeting the insulin-like growth factor type I receptor (IGF-IR) in cancer: The next EGFR?'

Dale L. Ludwig (ImClone Systems Inc., New York, USA)

11.50-12.10

'The power and promise of immunoglobulin repertoire analysis for cancer therapy'

Beatrix Kotlan (National Institute of Oncology, Budapest, Hungary)

12.10-14.00

Lunch Break Et Posters

SESSION 3:

CANCER II

Moderator: H. Peter Vollmers (University of Wurzburg, Germany)

14.00-14.30

'Title to be confirmed'

Zdenka K. Jonak (GSK, King-of-Prussia, Pennsylvania, USA)

14.30-14.50

'Natural human IgG antibodies as tools for cancer therapy'

Stephanie Brandlein (University of Wurzburg, Germany)

14.50-15.10

'Antibody-maytansinoid conjugates: A new generation of linkers to provide enhanced potency against target cancers'
Rajeeva Singh (ImmunoGen Inc., Waltham, Massachusetts, USA)

15.10-15.30

'Anti-ganglioside antibody-induced tumor cell death by membrane pore formation'

Cristina Mateo de Acosta, Lourdes Roque, Joel de Leon, Adriana Carr and Rolando Perez
(Center of Molecular Immunology, Havana, Cuba)

15.30-15.50

'IMC-1121B and IMC-A12 – Preliminary clinical experience with anti-VEGFR2 and anti-IGF-1R antibodies'

Jonathan D. Schwartz
(ImClone Systems Inc., Brachnburg, New Jersey, USA)

15.50-16.10

Tea Break Et Posters

SESSION 4:

ADVANCES IN TECHNOLOGY

Moderator: Mark Glassy (HAH 2008 Conference Chairman)

16.10-16.40

'What is the potential for antibody Fab' fragments?'

David P. Humphreys (UCB-Celltech, Slough, UK)

16.40-17.10

'Capturing the natural humoral immune response by Symplex'

John Haurum (Symphogen AS, Lyngby, Denmark)

17.10-17.30

'Anti-thrombopoietin receptor agonist antibodies improved by domain-subclass conversion'

Masayuki Kai, Kazuhiro Motoki, Hideaki Yoshida, Hiroshi Miyazaki and Shiro Kataoka
(Kirin Pharma Co. Ltd., Japan)

17.30-17.50

'Plant farming of antifungal recombinant antibodies'

C. Capodicasa, A. Torosantucci, P. Chiana, C. Bromuro, A. Cassone and E. Benvenuto (ENEA, Rome, Italy)

17.50-18.10

'The humanization of pharmaceutical glycoproteins using targeted expression or trapping in the plant secretory pathway'

V. Gomord and L. Faye (CNRS-University of Rouen, France)

HAH 2008 Welcome Reception Et Poster Session

HAH 2008 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/hah_2008

Conference Program – Thursday 13th November 2008

SESSION 5:

HIV

Moderator: Mirek Gorny (*New York University, USA*)

08.30–09.00

'Immunoglobulin gene usage by human monoclonal antibodies that neutralize HIV-1 by targeting the envelope V3 region'Miroslaw K. Gorny, Xiao-Hong Wang, Xunqing Jiang, Constance Williams, Barbara Volsky, Kathy Revesz, Bradley Witover, Arthur Nadas, Susan Zolla-Pazner and Xiang-Peng Kong
(*New York University School of Medicine, New York, USA*)

09.00–09.20

'Inhibition of HIV-1 infectivity through an innate mechanisms involving naturally occurring IgM anti-leukocyte autoantibodies'Peter I. Lobo, Kailo H. Schlegel, Wen Yuan, Gregory C. Townsend and Jennifer A. White
(*University of Virginia Health System, Charlottesville, Virginia, USA*)

09.20–09.50

'Use of human monoclonal antibodies in the design of vaccines against HIV-1'Susan Zolla-Pazner
(*New York University School of Medicine, New York, USA*)

09.50–10.20

'Novel method to generate anti-HIV human monoclonal antibodies'Mark Hicar, Xuemin Chen, Spyros Kalams, Paul Spearman and James E. Crowe Jr.
(*Vanderbilt University, Nashville, Tennessee, USA*)

10.20–10.40

'Structural basis of the antibody-antigen interaction in human anti-V3 HIV-1 monoclonal antibodies'Valicia Burke, Xunqiang Jiang, Constance Williams, Miroslaw K. Gorny, Susan Zolla-Pazner and Xiang-Peng Kong
(*New York University school of Medicine, New York, USA*)

10.40–11.00

Coffee Break & Posters

SESSION 6:

INFECTIOUS DISEASES

Moderator: Roberto Burioni
(*Universita Vita-Salute San Raffaele, Milan, Italy*)

11.00–11.30

'Human monoclonal antibodies against viral diseases: a clinical perspective'Roberto Burioni
(*Universita Vita-Salute San Raffaele, Milan, Italy*)

11.30–12.00

'An influenza N1 neuraminidase-specific monoclonal antibody protects animal against live challenge with homologous H5N1 virus'Vidadi Yusibov, Gene A. Palmer, Robert Nardone, Yoko Shoji, Jessica A. Chichester and Vadim Mett
(*Fraunhofer USA, Newark, Delaware, USA*)
Varough Deyde, Larisa Gubareva and Alexander Klimov
(*CDC, Atlanta, USA*)

12.00–12.20

'Isolation of broadly cross-neutralising and protective monoclonal antibodies against influenza virus'Mark Throsby (*Merus Biopharmaceuticals B.V., The Netherlands*)

12.20–12.40

'A unique class of protective human anti-M2 mAbs for pandemic influenza'Matthew Moyle (*Spaltudaq Corporation, Washington, USA*)

12.40–13.00

'Wide spectrum, protective anti- β -glucan antibodies: inhibitors of microbial virulence'Antonio Cassone (*Istituto Superiore di sanita, Rome, Italy*)

13.00–13.20

'Construction and biological characterization of an anti-Venezuelan equine encephalitis virus humanized antibody'Wei-Gang Hu, Amanda Phelps, Scott Jager, Damon Chau, Wendy Butcher, Lin Eastaugh, Stuart Perkins, Amanda Gates, Bob Phillpotts and Les P. Nagata (*Defence Research Et Development Canada, Medicine Hat, Alberta, Canada*)

13.20–14.30

Lunch Break & Posters

SESSION 7:

THERAPEUTIC ANTIBODIES: INFECTION

Moderator: Alois Lang (*GeNeuro SA, Geneva, Switzerland*)

14.30–15.00

'The therapeutic potential of monoclonal anti-human endogenous retrovirus W (HERV-W) envelope protein antibody in multiple sclerosis: results from a new EAE-animal model'Alois Lang (*GeNeuro SA, Geneva, Switzerland*)

15.00–15.30

'Development of a HuCAL GOLD[®] human monoclonal antibody for the therapeutic treatment of inflammatory diseases'Matthew Downham (*Morphosys AG, Martinsried, Germany*)

Continued overleaf

HAH 2008 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/hah_2008

Conference Program – Thursday 13th November 2008

15.30-16.00

'Creation of hybridoma populations from post-germinal center B-cells and their use to clone human antibodies specific for botulinum neurotoxins'
 Sharad P. Adekar and Scott Dessain (*Lankenau Institute for Medical Research, Wynnewood, Pennsylvania, USA*)

16.00-16.20

'Targeting viral antigens with radiolabeled antibodies as a novel approach to treatment of viral infections and virus-associated cancers'

E. Dadachova, X.G. Wang, M.C. Patel, E. Revskaya, R.A. Bryan, A. Morgenstern, C. Apostolidis, H. Goldstein, M. Gorny, S. Zolla-Pazner and A. Casadevall (*AECOM, New York, USA*)

16.20-16.40

Tea Break & Posters

SESSION 8:

IMMUNOMODULATION

Moderator: Mark Glassy (*HAH 2008 Conference Chairman*)

16.40-17.10

'Antibodies at the cross-roads of regenerative medicine'
 Jim Larrick (*Panorama Research Inc., California, USA*)

17.10-17.30

'Alteration of HIV gp120 antigenicity and immunogenicity by antibodies to the CD4-binding site of gp120'


Catarina E. Hioe, Maria Luisa Visciano, Miroslaw K. Gorny and Michael Tuen

(*New York University School of Medicine, New York, USA*)

Free Evening For Delegates

Sponsors

The HAH 2008 Scientific Advisory Committee and the organizers would like to acknowledge the support of the following sponsors:



HAH 2008 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
 Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
 Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/hah_2008

Provisional Conference Program – Friday 14th November 2008**SESSION 9:
THERAPEUTIC ANTIBODIES: CANCER**

Moderator: Zdenka Jonak
(GlaxoSmithKline, King-of-Prussia, USA)

09.00–09.30

'Anticancer therapeutic antibody targeting cancer cell and tumor-associated activities'

Yan Wu (ImClone Systems Inc., New York, USA)

09.30–10.00

'A variant IgG1 mediating improved ADCC'

John Lund, Ross Stewart, Michaela Levens, George Thom, Gulin Guler-Gane, Robert Holgate, Chris Gee, Dave Spencer, Carl Webster and Lutz Jermutus
(Medimmune Ltd, Cambridge, UK)

10.00–10.30

'Humanised anti-MUC1 antibody (AS1402) for the treatment of advanced breast cancer'

Nigel Courtenay-Luck (Antisoma Research Ltd, London, UK)

10.30–11.00

Coffee Break & Posters

11.00–11.30

'Targeting proteases for antibody therapeutic intervention in oncology'

Christopher Scott and Paul J. Kerr
(Fusion Antibodies, Northern Ireland, UK)

11.30–11.50

'Development of a potent anti-TYRP1 fully human antibody for melanoma therapy'

Xiaoqiang Kang (ImClone Systems Inc., New York, USA)

11.50–12.20

'Case study of DXL625 (CD20): A new platform for augmenting antibody therapeutics for cancer'

Jur Strobos
(InNexus Biotechnology Inc., British Columbia, Canada)

12.20–12.50

KEYNOTE:

'Monoclonal antibodies to the T cell receptor (TCR α) in cancer and infectious disease'

Jon Weidanz (Receptor Logic Ltd., Amarillo, Texas, USA)

12.50–14.00

Lunch Break & Posters

**SESSION 10:
NEW APPROACHES**

Moderator: Mark Glassy (HAH 2008 Conference Chairman)

14.00–14.30

'Therapeutic cDNA vaccines and disease-specific monoclonal antibodies, which target CD44 on cancer and inflammatory cells'

David Naor (Hebrew University of Jerusalem, Israel)

14.30–14.50

'New applications for rapid discovery of high value hybridomas and stable therapeutic antibody producing cells using ClonePix FL'

Christopher J. Mann (Genetix Ltd., New Milton, Hampshire, UK)

14.50–15.10

'The high affinity and potent XOMA 052 anti-IL-1 β antibody: designed with a goal in mind'

Linda Masat (XOMA (US) LLC, Berkeley, California, USA)

15.10–15.30

'VelocImmune: A novel platform for human antibody discovery'

Sean Stevens
(Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA)

15.30–16.00

'Manipulation of T cell populations with cytokine/mAb complexes'

Charles D. Surh
(Scripps Research Institute, La Jolla, California, USA)

16.00–16.30

REVIEW:

'Thirty years of human monoclonal antibodies: past, present and future developments'

Michael Steinitz (The Hebrew University-Hadassah Medical School, Jerusalem, Israel)

Closing Remarks

Mark Glassy (HAH 2008 Conference Chairman)

* THIS ORAL/POSTER PROGRAM IS CORRECT AT TIME OF PRINTING. HOWEVER THE ORGANIZERS RESERVE THE RIGHT TO MAKE ANY ALTERATIONS THAT MAY BE REQUIRED IN THE INTERESTS OF THE FINAL CONFERENCE PROGRAM.

HAH 2008 Conference Secretariat, Meetings Management

The Barn, Rake Meadow, Station Lane, Milford, Surrey, GU8 5AD, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
Email: csumner@meetingsmgmt.u-net.com Register securely on-line at: www.meetingsmanagement.com/hah_2008